Loading use case index…
Loading use case index…
AI use case
Amgen undertook a deliberate multi-phase deployment of generative AI tools, scaling from 300 Microsoft Copilot users in late 2023 to all 20,000 employees by mid-2024, then expan…
Core facts from this catalog record. Primary narrative lives in the hero above; full raw fields follow in the next section.
Every column from the source row, in stable order. URLs open in a new tab.
Title
Generative AI Deployment to 20,000 Employees: Microsoft Copilot and ChatGPT Enterprise at Amgen
Content
Amgen is a US-based biotechnology company and one of the world leading independent biotechnology firms. In 2023-2025, Amgen undertook a deliberate multi-phase deployment of generative AI tools. The company initially equipped just 300 employees with Microsoft 365 Copilot in late 2023 and scaled to 20,000 users by mid-2024. A year after first deploying Copilot, Amgen began broader use of ChatGPT Enterprise in 2024, citing strong employee preference and positive feedback. Internal surveys confirmed high user satisfaction: scientists and staff found ChatGPT effective for tasks like analyzing data and drafting reports. Amgen deployed its AI governance framework aligned with NIST Trustworthy AI principles, with security and compliance guardrails embedded throughout the process. Amgen tracked adoption through user counts, usage logs, and employee feedback. Amgen CTO and SVP reported daily use of AI tools and integration from the office to the lab. Executives observed that Copilot and ChatGPT helped streamline routine tasks, enabling staff to focus on high-value research and innovation. The company emphasized measured testing supported by security, enabling integration of technology into meaningful workflows. This comprehensive report examines Amgen AI adoption as a case study and situates it within broader industry trends including comparison with Moderna, Pfizer, and Johnson & Johnson.
Continue exploring AI deployments in the catalog.
Back to use casesCity
Thousand Oaks
Company/Organization
Amgen
Continent
North America
Country
United States
Category
Biotechnology
Type
Deployment
Id
904f6f33-3404-4f88-a223-8a96148e2350
Created At
2026-04-19T23:22:03.560023+00:00